Subramanian S, Rajendiran M, Paramasivam M, Murugesan I, Palani S, Velusamy S. Advances in SGLT2 Inhibitor Therapy: Comparative Evidence for Empagliflozin and Dapagliflozin in Cardio-Renal-Metabolic Disorders. International Journal of Advancement in Life Sciences Research [Internet]. 31Oct.2026 [cited 12Nov.2026];9(4):56-8. Available from: https://www.ijalsr.org/index.php/journal/article/view/1443